论文部分内容阅读
目的:评价南京地区喹诺酮类药的利用情况。方法:对南京地区34家医院2012~2014年喹诺酮类药的销售金额、用药频度(DDDs)和限定日费用(DDC)等进行回顾性统计分析。结果:该地区医院2012~2014年喹诺酮类销售金额和DDDs呈小幅增长趋势,复合年均增长率(CAGR)分别为3.35%、0.09%。3年中,莫西沙星的DDDs和销售金额均排名第一,且逐年上升。左氧氟沙星销售金额小幅下降,但DDDs小幅增长。洛美沙星DDDs和销售金额下降趋势较明显,2013年淘汰3种喹诺酮类药(依诺沙星、氟罗沙星、司帕沙星)。结论:该地区医院喹诺酮类药的应用呈上升趋势,但为防止临床滥用以延缓细菌耐药性的产生,建议严格控制喹诺酮类药的应用,以确保临床用药安全、有效和经济。
Objective: To evaluate the use of quinolones in Nanjing. Methods: Retrospective statistical analysis was conducted on the sales amount, frequency of medication (DDDs) and DDC of quinolones in 34 hospitals in Nanjing in 2012-2014. Results: The sales volume and DDDs of quinolones increased slightly in 2012 ~ 2014 in the district hospitals, with CAGR of 3.35% and 0.09% respectively. In three years, moxifloxacin ranks first in terms of DDDs and sales volume, and has been increasing year by year. Levofloxacin sales decreased slightly, but DDDs increased slightly. Lomefloxacin DDDs and the sales volume decreased more obviously. In 2013, three quinolones (enoxacin, fleroxacin, sparfloxacin) were eliminated. CONCLUSIONS: The use of quinolones in hospitals in the region is on the rise. However, in order to prevent clinical abuse and delay the development of bacterial resistance, it is recommended to strictly control the application of quinolones to ensure the safety, effectiveness and economy of clinical use.